Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2014 (2014), Article ID 469059, 12 pages
http://dx.doi.org/10.1155/2014/469059
Research Article

Dietary Blueberry and Bifidobacteria Attenuate Nonalcoholic Fatty Liver Disease in Rats by Affecting SIRT1-Mediated Signaling Pathway

1Biochemistry Department, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou 550004, China
2Guiyang Medical College, Guiyang, Guizhou 550004, China
3Department of Infectious Diseases, Affiliated Hospital of Guiyang Medical College, 28 Guiyi Street, Guiyang, Guizhou 550004, China

Received 22 August 2014; Revised 1 November 2014; Accepted 3 November 2014; Published 27 November 2014

Academic Editor: Cinzia Signorini

Copyright © 2014 Tingting Ren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Shen, J.-G. Fan, Y. Shao et al., “Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey,” World Journal of Gastroenterology, vol. 9, no. 5, pp. 1106–1110, 2003. View at Google Scholar · View at Scopus
  2. Y. Cigremis, H. Turel, K. Adiguzelet et al., “The effects of acute acetaminophen toxicity on hepatic mRNA expression of SOD, CAT, GSH-Px, and levels of peroxynitrite, nitric oxide, reduced glutathione, and malondialdehyde in rabbit,” Molecular and Cellular Biochemistry, vol. 323, no. 1-2, pp. 31–38, 2009. View at Publisher · View at Google Scholar
  3. G. Engelmann, G. F. Hoffmann, J. Grulich-Henn, and U. Teufel, “Alanine aminotransferase elevation in obese infants and children: a marker of early onset non alcoholic fatty liver disease,” Hepatitis Monthly, vol. 14, no. 4, Article ID e14112, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Sert, Ö. Pirgon, E. Aypar, H. Yilmaz, and B. Dündar, “Relationship between aspartate aminotransferase to-platelet ratio index and carotid intima-media thickness in obese adolescents with non-alcoholic fatty liver disease,” Journal of Clinical Research in Pediatric Endocrinology, vol. 5, no. 3, pp. 182–188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Fabbrini, B. S. Mohammed, K. M. Korenblat et al., “Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2727–2735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. D. C. Chan, G. F. Watts, S. Gan, A. T. Y. Wong, E. M. M. Ooi, and P. H. R. Barrett, “Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in Obesity,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 5, pp. 1043–1050, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Pacifico, E. Bonci, G. Andreoliet et al., “Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 24, no. 7, pp. 737–743, 2014. View at Google Scholar
  8. V. Nobili, B. Donati, N. Panera et al., “A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 58, no. 5, pp. 632–636, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Qiang, Y. Xu, Y. Lu et al., “Autofluorescence of MDA-modified proteins as an in vitro and in vivo probe in oxidative stress analysis,” Protein and Cell, vol. 5, no. 6, pp. 484–487, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. A. R. Sayed, “Ferulsinaic acid modulates SOD, GSH, and antioxidant enzymes in diabetic kidney,” Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 580104, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Suzuki, H. Takeuchi, T. Kakita, M. Unno, Y. Katayose, and S. Matsuno, “The involvement of the intracellular superoxide production system in hepatic ischemia-reperfusion injuryIn vivo and in vitro experiments using transgenic mice manifesting excessive CuZn-SOD activity,” Free Radical Biology and Medicine, vol. 29, no. 8, pp. 756–763, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Kotosai, S. Shimada, M. Kanda et al., “Plasma HDL reduces nonesterified fatty acid hydroperoxides originating from oxidized LDL: a mechanism for its antioxidant ability,” Lipids, vol. 48, no. 6, pp. 569–578, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Doycheva and R. Loomba, “Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD),” Advances in Therapy, vol. 31, no. 1, pp. 30–43, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. D. M. Riche, J. W. Fleming, S. S. Malinowski, C. A. Black, K. H. Miller, and M. R. Wofford, “Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome,” Annals of Pharmacotherapy, vol. 48, no. 1, pp. 137–141, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Zhang, H. Xiang, Y. Fan et al., “The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials,” Endocrine, vol. 44, no. 3, pp. 648–658, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Dodiya, V. Kale, S. Goswami, R. Sundar, and M. Jain, “Evaluation of adverse effects of lisinopril and rosuvastatin on hematological and biochemical analytes in wistar rats,” Toxicology International, vol. 20, no. 2, pp. 170–176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Valenti, P. Riso, A. Mazzocchi, M. Porrini, S. Fargion, and C. Agostoni, “Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 145421, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. S. M. Bornsek, L. Ziberna, T. Polak et al., “Bilberry and blueberry anthocyanins act as powerful intracellular antioxidants in mammalian cells,” Food Chemistry, vol. 134, no. 4, pp. 1878–1884, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Li, H. Sun, J. Pei et al., “De novo sequencing and comparative analysis of the blueberry transcriptome to discover putative genes related to antioxidants,” Gene, vol. 511, no. 1, pp. 54–61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Wang, M. Cheng, B. Zhang, F. Nie, and H. Jiang, “Dietary supplementation of blueberry juice enhances hepatic expression of metallothionein and attenuates liver fibrosis in rats,” PLoS ONE, vol. 8, no. 3, Article ID e58659, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. O. K. Chang, K.-H. Seol, S.-G. Jeong et al., “Casein hydrolysis by Bifidobacterium longum KACC91563 and antioxidant activities of peptides derived therefrom,” Journal of Dairy Science, vol. 96, no. 9, pp. 5544–5555, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. Q. Shen, N. Shang, and P. Li, “In vitro and in vivo antioxidant activity of bifidobacterium animalis 01 isolated from centenarians,” Current Microbiology, vol. 62, no. 4, pp. 1097–1103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Osman, D. Adawi, S. Ahrné, B. Jeppsson, and G. Molin, “Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry,” Digestive and Liver Disease, vol. 39, no. 9, pp. 849–856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Colak, A. Yesil, H. H. Mutluet et al., “A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators,” Journal of Gastrointestinal and Liver Diseases, vol. 23, no. 3, pp. 311–319, 2014. View at Publisher · View at Google Scholar
  25. M. P. Gillum, D. M. Erion, and G. I. Shulman, “Sirtuin-1 regulation of mammalian metabolism,” Trends in Molecular Medicine, vol. 17, no. 1, pp. 8–13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Purushotham, T. T. Schug, Q. Xu, S. Surapureddi, X. Guo, and X. Li, “Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation,” Cell Metabolism, vol. 9, no. 4, pp. 327–338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Deplanque, P. Gelé, O. Pétrault et al., “Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment,” Journal of Neuroscience, vol. 23, no. 15, pp. 6264–6271, 2003. View at Google Scholar · View at Scopus
  28. W. M. Sun, Y. P. Wang, Y. Q. Duan et al., “Radix Hedysari polysaccharide suppresses lipid metabolism dysfunction in a rat model of nonalcoholic fatty liver disease via adenosine monophosphateactivated protein kinase pathway activation,” Molecular Medicine Reports, vol. 10, no. 3, pp. 1237–1244, 2014. View at Google Scholar
  29. L. Lamoureux, D. Roy, and S. F. Gauthier, “Production of oligosaccharides in yogurt containing bifidobacteria and yogurt cultures,” Journal of Dairy Science, vol. 85, no. 5, pp. 1058–1069, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Cano, F. Ciaffoni, G. M. Safwat et al., “Hepatic VLDL assembly is disturbed in a rat model of nonalcoholic fatty liver disease: is there a role for dietary coenzyme Q?” Journal of Applied Physiology, vol. 107, no. 3, pp. 707–717, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. G. B. Hunt, J. A. Luff, L. Daniel, and R. V. D. Bergh, “Evaluation of hepatic steatosis in dogs with congenital portosystemic shunts using oil red o staining,” Veterinary Pathology, vol. 50, no. 6, pp. 1109–1115, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Wang, R. A. Goulart, and L. Pantanowitz, “Oil red O staining in cytopathology,” Diagnostic Cytopathology, vol. 39, no. 4, pp. 272–273, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. T. Feldman and D. Wolfe, “Tissue processing and hematoxylin and eosin staining,” in Histopathology, vol. 1180 of Methods in Molecular Biology, pp. 31–43, Springer, New York, NY, USA, 2014. View at Publisher · View at Google Scholar
  34. K. Murakami, R. Takahashi, M. Ono et al., “Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen,” Journal of Gastroenterology, vol. 46, no. 9, pp. 1120–1126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Jelenik, U. Floegel, E. Phielixet et al., “Non-alcoholic fatty liver disease and insulin resistance are associated with increased cardiac oxidative stress in mice,” European Heart Journal, vol. 34, pp. 931–932, 2013. View at Google Scholar
  36. X. Dong, D. Li, H. Liu, and Y. Y. Zhao, “SOD3 and eNOS genotypes are associated with SOD activity and NOx,” Experimental and Therapeutic Medicine, vol. 8, no. 1, pp. 328–334, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Su, Q. Li, Y. liu et al., “Sesamin ameliorates doxorubicin-induced cardiotoxicity: Involvement of Sirt1 and Mn-SOD pathway,” Toxicology Letters, vol. 224, no. 2, pp. 257–263, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. S. M. Kumar, K. Swaminathan, D. L. Clemens, and A. Dey, “GSH protects against oxidative stress and toxicity in VL-17A cells exposed to high glucose,” European Journal of Nutrition, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Jung, O. Y. Kim, M. Kim, J. Song, S. H. Lee, and J. H. Lee, “Age-related increase in alanine aminotransferase correlates with elevated levels of plasma amino acids, decanoylcarnitine, Lp-PLA2 activity, oxidative stress, and arterial stiffness,” Journal of Proteome Research, vol. 13, no. 7, pp. 3467–3475, 2014. View at Publisher · View at Google Scholar
  40. J. Yamada, H. Tomiyama, M. Yambeet et al., “Elevated serum alanine aminotransferase is a marker of inflammation and oxidative stress associated with the metabolic syndrome,” Journal of Hypertension, vol. 24, p. 193, 2006. View at Google Scholar
  41. H. H. Mansour, S. I. Nel, and H. F. Hafez, “Ameliorative effect of septilin, an ayurvedic preparation against γ-irradiation-induced oxidative stress and tissue injury in rats,” Indian Journal of Biochemistry and Biophysics, vol. 51, no. 2, pp. 135–141, 2014. View at Google Scholar · View at Scopus
  42. F. Paoletti and A. Mocali, “Determination of superoxide dismutase activity by purely chemical system based on NAD(P)H oxidation,” Methods in Enzymology, vol. 186, pp. 209–220, 1990. View at Publisher · View at Google Scholar · View at Scopus
  43. P. J. Hissin and R. Hilf, “A fluorometric method for determination of oxidized and reduced glutathione in tissues,” Analytical Biochemistry, vol. 74, no. 1, pp. 214–226, 1976. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Gastaldelli, M. Gaggini, and L. Mezzabotta, “Alteration in lipid metabolism after an oral fat load in subjects with NAFLD,” Diabetologia, vol. 56, p. S323, 2013. View at Publisher · View at Google Scholar
  45. G. Musso, R. Gambino, and M. Cassader, “Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD),” Progress in Lipid Research, vol. 48, no. 1, pp. 1–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. T. A. Gheita and S. A. Kenawy, “Measurement of malondialdehyde, glutathione, and glutathione peroxidase in SLE patients,” Methods in Molecular Biology, vol. 1134, pp. 193–199, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Colak, O. Ozturk, E. Senates et al., “SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease,” Medical Science Monitor, vol. 17, no. 5, article HY5-9, 2011. View at Google Scholar · View at Scopus
  48. N. Ziamajidi, S. Khaghani, G. Hassanzadehet et al., “Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARalpha and SREBP-1,” Food and Chemical Toxicology, vol. 58, pp. 198–209, 2013. View at Google Scholar
  49. A. E. Feldstein, B. G. Papouchado, P. Angulo, S. Sanderson, L. Adams, and G. J. Gores, “Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease,” Clinical Gastroenterology and Hepatology, vol. 3, no. 4, pp. 384–389, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Sumida, E. Niki, Y. Naito, and T. Yoshikawa, “Involvement of free radicals and oxidative stress in NAFLD/NASH,” Free Radical Research, vol. 47, no. 11, pp. 869–880, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Podrini, M. Borghesan, A. Greco, V. Pazienza, G. Mazzoccoli, and M. Vinciguerra, “Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD),” Current Pharmaceutical Design, vol. 19, no. 15, pp. 2737–2746, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. M. Alkassabany, A. G. Farghaly, and E. M. El-Ghitany, “Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt,” Arab Journal of Gastroenterology, vol. 15, no. 2, pp. 76–81, 2014. View at Publisher · View at Google Scholar
  53. S. Kalra, M. Vithalani, G. Gulati et al., “Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT),” Journal of Association of Physicians of India, vol. 61, no. 7, pp. 448–453, 2013. View at Google Scholar · View at Scopus
  54. M. Malespin, B. Sleesman, A. Lau, S. S. Wong, and S. J. Cotler, “Prevalence and correlates of suspected nonalcoholic fatty liver disease in Chinese American children,” Journal of Clinical Gastroenterology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. J. A. López-Velázquez, K. V. Silva-Vidal, G. Ponciano-Rodríguez et al., “The prevalence of nonalcoholic fatty liver disease in the Americas,” Annals of Hepatology, vol. 13, no. 2, pp. 166–178, 2014. View at Google Scholar · View at Scopus
  56. G. F. Watts, “Nutrition and metabolism: nutritional therapy for disordered triglyceride metabolism and nonalcoholic fatty liver disease,” Current Opinion in Lipidology, vol. 21, no. 6, pp. 545–547, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. D. B. Andrews and J. E. Lavine, “Medical therapy for nonalcoholic fatty liver disease in children and adolescents,” Expert Review of Gastroenterology and Hepatology, vol. 6, no. 1, pp. 1–3, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Eckard, R. Cole, J. Lockwood et al., “Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial,” Therapeutic Advances in Gastroenterology, vol. 6, no. 4, pp. 249–259, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Tock, A. R. Dâmaso, A. de Piano et al., “Long-term effects of metformin and lifestyle modification on nonalcoholic fatty liver disease obese adolescents,” Journal of Obesity, vol. 2010, Article ID 831901, 6 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. R. C. Smith, “Metformin as a treatment for antipsychotic drug side effects: special focus on women with schizophrenia,” The American Journal of Psychiatry, vol. 169, no. 8, pp. 774–776, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. M. H. Marhamatizadeh, E. Ehsandoost, P. Gholami, and M. Nazemi, “Effect of Denak (Oliverici decumbens Vent) on growth and survival of Lactobacillus acidophilus and Bifidobacterium bifidum for production of probiotic herbal milk and yoghurt,” Pakistan Journal of Biological Sciences, vol. 16, no. 24, pp. 2009–2014, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Bellavia, F. Rappa, M. Lo Belloet et al., “Lactobacillus casei and bifidobacterium lactis supplementation reduces tissue damage of intestinal mucosa and liver after 2,4,6-trinitrobenzenesulfonic acid treatment in mice,” Journal of Biological Regulators and Homeostatic Agents, vol. 28, no. 2, pp. 251–261, 2014. View at Google Scholar
  63. İ. Bingül, C. Başaran-Küçükgergin, M. S. Tekkeşin, V. Olgaç, S. Doğru-Abbasoğlu, and M. Uysal, “Effect of blueberry pretreatment on diethylnitrosamine-induced oxidative stress and liver injury in rats,” Environmental Toxicology and Pharmacology, vol. 36, no. 2, pp. 529–538, 2013. View at Publisher · View at Google Scholar
  64. B. T. Jeon, R. W. Heo, H. J. Shin et al., “Attenuation by a Vigna nakashimae extract of nonalcoholic fatty liver disease in high-fat diet-fed mice,” Bioscience, Biotechnology, and Biochemistry, vol. 78, no. 3, pp. 482–489, 2014. View at Publisher · View at Google Scholar
  65. J. Liu, Z. J. Zhuang, D. X. Bian et al., “Toll-like receptor-4 signalling in the progression of non-alcoholic fatty liver disease induced by high-fat and high-fructose diet in mice,” Clinical and Experimental Pharmacology and Physiology, vol. 41, no. 7, pp. 482–488, 2014. View at Google Scholar
  66. Y. Dai and D. V. Faller, “Transcription regulation by class III histone deacetylases (HDACs)—sirtuins,” Translational Oncogenomics, vol. 2008, no. 3, pp. 53–65, 2008. View at Google Scholar · View at Scopus
  67. Y. Colak, O. Ozturk, E. Senates et al., “SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease,” Medical Science Monitor, vol. 17, no. 5, pp. Hy5–Hy9, 2011. View at Google Scholar · View at Scopus
  68. Y. P. Wang, M. L. Cheng, B. F. Zhang et al., “Effect of blueberry on hepatic and immunological functions in mice,” Hepatobiliary and Pancreatic Diseases International, vol. 9, no. 2, pp. 164–168, 2010. View at Google Scholar · View at Scopus
  69. Y. Yang, W. Li, Y. Liu et al., “Alpha-lipoic acid improves high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1, FoxO1 and Nrf2 via the SIRT1/LKB1/AMPK pathway,” The Journal of Nutritional Biochemistry, vol. 25, no. 11, pp. 1207–1217, 2014. View at Publisher · View at Google Scholar
  70. M. Xu, B. Wang, Y. Fu et al., “Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease,” Microbial Ecology, vol. 63, no. 2, pp. 304–313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. B. Ponugoti, D. H. Kim, Z. Xiao et al., “SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism,” Journal of Biological Chemistry, vol. 285, no. 44, pp. 33959–33970, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Wang, R. Teng, L. Di et al., “PPARa and sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders,” Diabetes, vol. 62, no. 12, pp. 4122–4131, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Correa-Betanzo, E. Allen-Vercoe, J. McDonald, K. Schroeter, M. Corredig, and G. Paliyath, “Stability and biological activity of wild blueberry (Vaccinium angustifolium) polyphenols during simulated in vitro gastrointestinal digestion,” Food Chemistry, vol. 165, pp. 522–531, 2014. View at Publisher · View at Google Scholar
  74. E. Ozcelik, S. Uslu, D. Burukoglu et al., “Chitosan and blueberry treatment induces arginase activity and inhibits nitric oxide production during acetaminophen-induced hepatotoxicity,” Pharmacognosy Magazine, vol. 10, supplement 2, pp. S217–S224, 2014. View at Google Scholar
  75. Y. Zhao, F. Ling, T. M. Griffin et al., “Up-regulation of the Sirtuin 1 (Sirt1) and Peroxisome Proliferator-activated Receptor γ Coactivator-1α (PGC-1α) Genes in White Adipose Tissue of Id1 Protein-deficient Mice: IMPLICATIONS IN THE PROTECTION AGAINST DIET AND AGE-INDUCED GLUCOSE INTOLERANCE,” The Journal of Biological Chemistry, vol. 289, no. 42, pp. 29112–29122, 2014. View at Google Scholar
  76. C. Feillet-Coudray, M. Aoun, G. Fouret et al., “Effects of long-term administration of saturated and n-3 fatty acid-rich diets on lipid utilisation and oxidative stress in rat liver and muscle tissues,” British Journal of Nutrition, vol. 110, no. 10, pp. 1789–1802, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. R. C. Khanal, L. R. Howard, C. R. Brownmiller, and R. L. Prior, “Influence of extrusion processing on procyanidin composition and total anthocyanin contents of blueberry pomace,” Journal of Food Science, vol. 74, no. 2, pp. H52–H58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Li, L. Chen, T. Yang et al., “Increasing antioxidant activity of procyanidin extracts from the pericarp of Litchi chinensis processing waste by two probiotic bacteria bioconversions,” Journal of Agricultural and Food Chemistry, vol. 61, no. 10, pp. 2506–2512, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Zhong and H. Cong, “Inhibition of grape procyanidin on the expression of SSTR-2 mRNA in the hepatic cells induced by N-nitroso compounds,” Wei Sheng Yan Jiu, vol. 33, no. 4, pp. 430–432, 2004. View at Google Scholar · View at Scopus
  80. T. S. Plantinga, W. W. C. Van Maren, J. Van Bergenhenegouwen, and ETAL, “Differential toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics,” Clinical and Vaccine Immunology, vol. 18, no. 4, pp. 621–628, 2011. View at Publisher · View at Google Scholar · View at Scopus